Treating cancer when pRb and p53 cannot be reactivated.
Activation of oncoproteins and inactivation of tumor suppressors induces tumorigenesis. When these events happen upstream of pRb and p53, cancer therapies may initially succeed and then fail when pRb and p53 are activated and then re-inactivated. Therapies might succeed if they remain effective when pRb and p53 are genetically inactivated.
Department of Developmental & Molecular Biology, and Ophthalmology & Visual Sciences, and Medicine; The Albert Einstein Comprehensive Cancer Center and Liver Research Center; Albert Einstein College of Medicine ; Bronx, NY, USA.
Liang
L
Zhu
Skp2; cancer therapy; genetic inactivation; miR-17-92; p53; pRb